Cinctive Capital Management LP Increases Holdings in Merck & Co., Inc. $MRK

Cinctive Capital Management LP boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 88.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,482 shares of the company’s stock after purchasing an additional 41,456 shares during the period. Cinctive Capital Management LP’s holdings in Merck & Co., Inc. were worth $7,426,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in MRK. Darwin Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $27,000. Barnes Dennig Private Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares in the last quarter. Bare Financial Services Inc raised its holdings in shares of Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares during the period. Finally, United Financial Planning Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Down 0.3%

NYSE:MRK opened at $115.61 on Friday. The stock has a market cap of $285.84 billion, a price-to-earnings ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The business’s 50-day simple moving average is $115.26 and its 200 day simple moving average is $99.68.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the firm earned $1.72 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRK. Citigroup upped their price target on Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a research note on Thursday, January 8th. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Finally, The Goldman Sachs Group raised their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.81.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.